To better understand the most common quality issues currently experienced by biopharmaceutical companies, Syneos Health conducted an analysis of 1,545 findings emerging from 281 mock audits.
In this white paper, our experts examine the results of these audits and identified the most prevalent quality issues by type, region, company size, category and root cause, and provide key recommendations to minimize the risk of findings for companies of all sizes.
Download the white paper below
